- Home
- CTO vs BBNX Comparison
CTO vs BBNX Comparison
Compare CTO & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | BBNX |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | 42 | 423 |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 493.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CTO | BBNX |
|---|---|---|
| Price | $20.23 | $9.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $21.50 | ★ $23.80 |
| AVG Volume (30 Days) | 163.6K | ★ 1.2M |
| Earning Date | 04-28-2026 | 04-21-2026 |
| Dividend Yield | ★ 7.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | $34.90 |
| Revenue Next Year | $2.76 | $34.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $8.80 |
| 52 Week High | $20.25 | $32.71 |
Technical Indicators
Market Signals| Indicator | CTO | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 66.86 | 39.09 |
| Support Level | $19.22 | $9.36 |
| Resistance Level | N/A | $11.92 |
| Average True Range (ATR) | 0.33 | 1.14 |
| MACD | 0.03 | -0.12 |
| Stochastic Oscillator | 72.39 | 23.19 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.